Understanding Duchenne muscular dystrophy-associated brain pathology
Open accessThe DOI matches its Crossref record; 203 of the 204 references it cites were found in a registry or an index; none of the 273 sources its claims cite is checked for support yet.
Abstract
The most common neuromuscular disorder, Duchenne muscular dystrophy (DMD), is caused by mutations in the DMD gene, resulting in a lack of dystrophin. In addition to severe and progressive muscle wasting, a subset of individuals with DMD experience, to largely varying extents, behavioural and cognitive deficits, including a lower IQ, and neurological comorbidities, such as autism spectrum disorder, obsessive compulsive disorder and attention deficit hyperactivity disorder. Neuroimaging studies in individuals with DMD have identified widespread pathology, including structural, physiological and connective alterations. DMD mouse models exhibit a number of DMD-associated behavioural traits, including anxiety, social deficits and learning disabilities, and have been used to investigate DMD brain pathology. Although there are currently no therapies to treat DMD brain pathology, genetic approaches are being developed to restore dystrophin expression. In particular, the exon skipping approach shows promise in ameliorating certain DMD-associated behavioural deficits in preclinical settings. However, the therapeutic potential of postnatal restoration of dystrophin isoforms involved in neurodevelopment is unknown. Furthermore, challenges such as low dystrophin restoration efficacy and translatability from DMD mouse models to the clinic remain to be addressed.
Overview
CoChat Summary
TL;DR
This review synthesizes human and preclinical evidence that Duchenne muscular dystrophy (DMD) involves brain pathology beyond muscle, with cognitive/behavioural deficits in ∼30% of individuals and widespread neuroimaging, neurochemical and synaptic alterations. It highlights DMD mouse models and preclinical exon-skipping approaches that partially restore brain dystrophin and improve some behavioural phenotypes, while noting major gaps in efficacy, translatability and postnatal restoration of neurodevelopmental isoforms.
Key findings
- About 30% of individuals with DMD have cognitive/behavioural deficits; average IQ is reported as mean=84.76 versus general population mean=100, with comorbidities including ASD ∼6%, OCD ∼7%, ADHD ∼16% and epileptic seizures 5%.
- Neuroimaging in DMD shows decreased total brain volume and global grey matter reductions, white matter microstructural deficits (increased diffusivity, lower fractional anisotropy), default mode network hyperconnectivity, reduced cerebral blood flow and altered motor cortex function; some changes are more pronounced in individuals lacking both Dp427 and Dp140, but findings are inconsistent.
- DMD mouse models show behavioural phenotypes including severe restraint-induced freezing in mdx/bl10 lasting at least 1 h, anxiety that worsens with loss of Dp140 and all isoforms, learning/memory deficits, social deficits and altered ultrasonic vocalizations; DMD-null mice also show restless behaviour and altered day/night rhythms.
- Preclinical exon skipping in mdx/bl10 and mdx52 mice restores dystrophin at low levels (e.g. 5–25% in several studies; exon 53 skipping restored 1% Dp427 and 5% Dp140 in one study) and can improve fear, anxiety or ASD-like behaviour, but postnatal restoration of Dp140 and Dp427p remains of unknown therapeutic value.
Methods
- Design: narrative review of DMD-associated brain pathology, animal models and therapy development, with a focus on exon skipping for brain dystrophin restoration.
- Data/sample: published human post-mortem, neuroimaging, neuropsychological and clinical literature, plus preclinical studies in mouse, rat, dog and pig DMD models; no primary data were generated.
- Main analysis: qualitative synthesis of cited studies, including summary tables of behavioural deficits in DMD mouse models (Table 1) and exon-skipping approaches in the DMD mouse brain (Table 2).
Limitations
- Stated in the paper: clinical neuroimaging studies are limited by small sample sizes (often ∼15 participants), underrepresentation of distal mutations affecting multiple/all dystrophin isoforms, variability in corticosteroid regimens/dosages/duration, and largely correlative findings that cannot establish causality.
- Stated in the paper: DMD mouse models are usually steroid-naïve, differ from humans in brain complexity and dystrophin isoform spatiotemporal expression, and face challenges of low dystrophin restoration efficacy and limited translatability to the clinic.
- Evident from the text: as a narrative review, it does not systematically appraise or meta-analyze the literature, and it repeatedly notes conflicting or inconclusive findings across studies, including inconsistent anxiety, depressive-like behaviour, memory and neuroimaging results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
0 Valid · 4 Not valid · 159 Not checked · 78 Own results and interpretations
None of the sources cited for this claim have been checked yet.
In the paper
“attention deficit hyperactivity disorder (ADHD; ∼16%) (Hendriksen and Vles, 2008; Ricotti et al., 2016; Darmahkasih et al., 2020; Pascual-Morena et al., 2023)”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Behavioural deficits and brain pathology in DMD
What the sources say
- Not checked yetcites Hendriksen and Vles, 2008 matched to “Neuropsychiatric Disorders in Males With Duchenne Muscular Dystrophy: Frequency Rate of Attention-Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder, and Obsessive—Compulsive Disorder” (2008) source
- Not checked yetcites Ricotti et al., 2016 matched to “Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations” (2016) source
- Not checked yetcites Darmahkasih et al., 2020 matched to “Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy” (2020) source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Notably, mutations occurring downstream of exon 63 in the DMD gene have also been associated with more rapid progression of motor impairment in individuals with DMD, indicating that the specific mutation location influences the severity and timing of functional decline (Chesshyre et al., 2022; Muntoni et al., 2023).”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Behavioural deficits and brain pathology in DMD
What the sources say
- Not checked yetcites Chesshyre et al., 2022 matched to “Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy” (2022) source
- Not checked yetcites Muntoni et al., 2023 matched to “DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials” (2023) source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The average IQ of the DMD population (mean=84.76) is one standard deviation below that of the general population (mean=100) (Hinton et al., 2000; Cotton et al., 2001; Cyrulnik et al., 2008; Connolly et al., 2013; Weerkamp et al., 2022).”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Behavioural deficits and brain pathology in DMD
What the sources say
- Not checked yetcites Hinton et al., 2000 matched to “Poor verbal working memory across intellectual level in boys with Duchenne dystrophy” (2000) source
- Not checked yetcites Cotton et al., 2001 matched to “Intelligence and Duchenne muscular dystrophy: Full-Scale, Verbal, and Performance intelligence quotients” (2001) source
- Not checked yetcites Cyrulnik et al., 2008 matched to “Cognitive and adaptive deficits in young children with Duchenne muscular dystrophy (DMD)” (2008) source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“However, there remains notable variability in both motor and central nervous system (CNS) outcomes, even among individuals with mutations affecting the 3′ end of the gene, implying that mutation location alone does not fully explain the phenotypic differences (Fang et al., 2025).”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Behavioural deficits and brain pathology in DMD
What the sources say
- Not checked yetcites Fang et al., 2025 matched to “Association of DMD Gene Variant Classes With Motor Outcomes in a Drug Registration Clinical Trial Setting” (2025) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Approximately 30% of them have a higher risk of cognitive impairment, learning disabilities and delayed developmental milestones (Ricotti et al., 2016; Colombo et al., 2017; Darmahkasih et al., 2020).”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Behavioural deficits and brain pathology in DMD
What the sources say
- Not checked yetcites Ricotti et al., 2016 matched to “Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations” (2016) source
- Not checked yetcites Colombo et al., 2017 matched to “Assessing mental health in boys with Duchenne muscular dystrophy: Emotional, behavioural and neurodevelopmental profile in an Italian clinical sample” (2017) source
- Not checked yetcites Darmahkasih et al., 2020 matched to “Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy” (2020) source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
101 more claims
Create a free account to see all 241 claims and to verify the 249 references still open.
- Probably not a substantial claim. 32
- It may state two separate claims as one. 107
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Therapy development for the DMD brain > Exon skipping to treat the DMD brain
“| Mdx/bl10 | Tc-DNA | 23 | 200 mg/kg weekly | IV | 12 weeks | 2-4% | Low (not quantified) | Yes (fear response) | Goyenvalle et al., 2015 |”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Therapy development for the DMD brain > Exon skipping to treat the DMD brain
“Because tc-DNA AONs can cross the blood–brain barrier, this systemic treatment resulted in exon 23 skipping and in the restoration of ∼5% of full-length dystrophin compared to WT dystrophin levels as assessed by western blotting, which led to improvements in the restraint-induced fear response in this model.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Therapy development for the DMD brain > Exon skipping to treat the DMD brain
“This, in turn, resulted in a ∼25% increase in dystrophin levels (compared to WT levels) and improvements in the fear response.”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Therapy development for the DMD brain > Exon skipping to treat the DMD brain
“Dystrophin levels changed over time during this study and were highest 6-7 weeks after treatment (up to 15% of WT levels), and gradually decreased towards week 10.”
Citations
Cites
Items 201–203 of 203
Fang, Y., Dang, U. J., Illei, K. I., Clemens, P., Hoffman, E. P., & as the CINRG, V. D. I. (2025) · Neurology Genetics · doi:10.1212/nxg.0000000000200251 · Cited by 4
Counterman, K. J., Fatovic, K., Good, D. C., Martin, A. S., Dasgupta, S., & Anziska, Y. (2022) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-220821 · Cited by 4
(2021) · doi:10.36185/2532-1900-041
Cited by
Vacca, O., Doisy, M., Nagy, C., Saoudi, A., Phongsavanh, X., Coz, O. L., Vaillend, C., & Goyenvalle, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.09.757591 · Cited by 1
The Multi-System Roles of Dp71 Dystrophin Isoforms in Duchenne Muscular Dystrophy
Wilton-Clark, H., Raza, A., & Yokota, T. (2026) · Muscles · doi:10.3390/muscles5020043
Proteomics of Duchenne muscular dystrophy
Dowling, P., Swandulla, D., & Ohlendieck, K. (2026) · Advances in clinical chemistry · doi:10.1016/bs.acc.2026.10.003
Egiian, M., Eskandari, R., Tyler, S., Diop, M., & Hoffman, L. (2026) · Neuromuscular Disorders · doi:10.1016/j.nmd.2026.107463
Cao, Z., Yin, L., Zhang, X., Hong, E., Du, J., Liang, R., Tang, Y., & Zhang, G. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04863-y
Metadata
- Authors
- Verhaeg, M. A. T., Govaarts, R., & van Putten, M.
- Affiliations
- Leiden University Medical Center (NL)
- Corresponding author
- Govaarts, Rosanne
- van Putten, Maaike
- Venue
- Disease Models & Mechanisms
- Publisher
- The Company of Biologists
- Published
- 2025-07-01
- Volume
- 18
- Issue
- 7
- ISSN
- 1754-8403 (ISSN-L)
- 1754-8411
- PMC
- PMC12352290
- OpenAlex
- W4412820802
- Cited by
- 5
- References
- 204
- Citations by year
- 2026: 5
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Disease Models & Mechanisms (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Horizon 2020 Framework Programme (847826)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- Duchenne muscular dystrophy, neuropathology, dystrophin, DMD gene mutations, cognitive impairment, autism spectrum disorder, obsessive-compulsive disorder, attention deficit hyperactivity disorder, anxiety, social dysfunction, learning disabilities, exon skipping, dystrophin isoforms, brain development, behavioural deficits
- MeSH terms
- Animals, Brain, Disease Models, Animal, Humans, Dystrophin, Muscular Dystrophy, Duchenne, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.